Current Research Studies

SC-0105: Expanded Access Protocol for Tabelecleucel

SC-0105

  • Condition(s): Other Hematopoietic
  • Phase: N/A
  • Clinicaltrials.gov ID: NA

What is the goal of the study?

This is an expanded access protocol submitted to the FDA under IND #6834 which was received by the FDA on 17-OCT-2025 and approved on 12-NOV-2025. This product is an EBV-specific VST which already has EMA approval and had been nearing FDA approval this year before the timeline was disrupted. The investigator's brochure for Tabelecleucel is attached.

Who can participate in the study?

Please contact the study team listed below to learn more.

Study Team: